Eurotrials, which has bases in Portugal and Brazil, is focussed on providing Phase II and III stage clinical trials to drug developers.
The firm hopes AmeriStart will help it capitalise on demand for clinical trial capacity in “new” patient populations and predicts that South America will be the next region after Asia and central and Eastern Europe to benefit.
Company executive director Rui Melo said that: “Eurotrials provides local capabilities in Brazil and Latin America with the full support and oversight of their founding office in Portugal.”
“Our team of experienced physicians and clinicians has conducted clinical studies for many of the top American pharmaceutical companies.
“Now, with a representative office and AmeriStart’s organisational support, we hope to expand and improve our standing in the US marketplace,” added Melo.
Eurotrials is also keen to generate business from Big Pharma’s continuing efforts to expand in new drug markets such as those in Latin and South America.
Melo highlighted Brazil as “a key market for drug developers who need access to patient populations and ultimately, the Brazilian consumer.”
AmeriStart’s CEO, Jim Worrell, said that: “Because Eurotrials is a well-respected and leading CRO in Brazil, they are often able to navigate a shorter path through Brazil’s regulatory requirements and start a clinical trial sooner than you might expect.”
Worrell went on to say that: “Eurotrials has the added benefit of a second operational centre in Portugal for multi-centre trials that require European data. They are a one-stop shop for Latin America and Southern Europe.”
Ameristart’s roster of client contract research organisations include, Netherlands, Factory CRO, India’s Trident Life Sciences, Switzerland’s Swiss Pharma Contract and Hyderabad headquartered Vimta Labs.